|
FY2018
12 months to Dec 31, 2018
|
FY2017
12 months to Dec 31, 2017
|
FY2016
12 months to Dec 31, 2016
|
FY2015
12 months to Dec 31, 2015
|
FY2014
12 months to Dec 31, 2014
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||||
| Depreciation and amortization | |||||
| Bad debt expense | |||||
| Stock-based compensation | |||||
| Restricted stock non-cash compensation | |||||
| Compensation related to puttable common stock | |||||
| Acquisition related deferred compensation | |||||
| Changes in fair value of contingent consideration liability | |||||
| Change in fair value of warrant liability | |||||
| Other | |||||
| Amortization of Debt Discount (Premium) | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable and unbilled receivables | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Payment for Contingent Consideration Liability, Operating Activities | |||||
| Other liabilities | |||||
| Deferred revenue | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities: | |||||
| Capital expenditures | |||||
| Addition of capitalized software development costs | |||||
| Addition of intangible assets | |||||
| Acquisition, net of cash acquired | |||||
| Cash paid for deposits | |||||
| Increase (Decrease) in Restricted Cash | |||||
| Decrease (increase) in restricted cash | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from revolving line of credit | |||||
| Payments on revolving line of credit | |||||
| Proceeds from term loan | |||||
| Payments on term loan | |||||
| Debt financing costs | |||||
| Repayments on capital lease obligations | |||||
| Proceeds from the exercise of stock options | |||||
| Taxes paid related to net share settlement | |||||
| Proceeds from the exercise of common stock warrant | |||||
| Proceeds from initial public offering, net | |||||
| Payment for Contingent Consideration Liability, Financing Activities | |||||
| Net cash used in financing activities | |||||
| Effect of exchange rate on cash, cash equivalents and restricted cash | |||||
| Net decrease in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash and cash equivalents | |||||
| Restricted Cash | |||||
| Supplemental disclosures of cash flow information: | |||||
| Accretion of Series E Preferred Stock | |||||
| Accretion of Series A, B, C, D and E issuance costs | |||||
| Accretion of puttable common stock | |||||
| Cash paid for interest | |||||
| Non-cash property and equipment acquired under capital lease | |||||
| Non-cash property and equipment purchases in accounts payable | |||||
| Non-cash conversion of Series A, B, C, D and E preferred stock | |||||
| Non-cash acquisition contingent consideration | |||||
Loading...